Clearmind Medicine Inc. (CMND)Healthcare | Biotechnology | Vancouver, Canada | NasdaqCM
1.14 USD
+0.42
(58.421%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:58 p.m. EDT
BIO-trap with extreme downside risk despite positive drug news; recent 50-day volatility and negative forecast suggest a liquidity/technical squeeze that could lead to further declines below the 52-week low. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.406625 |
| MSTL | 0.731435 |
| AutoETS | 0.744722 |
| AutoARIMA | 1.005425 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.322 |
| Excess Kurtosis | -0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.097 |
| Market Cap | 2,730,078 |
| Beta | -1.03 |
| Previous Name | Cyntar Ventures Inc. |
| Website | https://www.clearmindmedicine.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9715 |
| Address1 | 1,220 West 6th Avenue |
| Address2 | Suite 101 |
| All Time High | 7,320.0 |
| All Time Low | 0.586 |
| Ask | 1.14 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 26,179,650 |
| Average Daily Volume3 Month | 4,512,600 |
| Average Volume | 4,512,600 |
| Average Volume10Days | 26,179,650 |
| Beta | -1.031 |
| Bid | 1.08 |
| Bid Size | 1 |
| Book Value | 5.493 |
| City | Vancouver |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.14 |
| Current Ratio | 3.794 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.52 |
| Day Low | 1.05 |
| Debt To Equity | 0.097 |
| Display Name | Clearmind Medicine |
| Ebitda | -7,819,964 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.018 |
| Enterprise Value | -7,957,988 |
| Eps Trailing Twelve Months | -24.12 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.02684 |
| Fifty Day Average Change | 0.113160014 |
| Fifty Day Average Change Percent | 0.11020219 |
| Fifty Two Week Change Percent | -97.15 |
| Fifty Two Week High | 52.4 |
| Fifty Two Week High Change | -51.260002 |
| Fifty Two Week High Change Percent | -0.9782443 |
| Fifty Two Week Low | 0.586 |
| Fifty Two Week Low Change | 0.55399996 |
| Fifty Two Week Low Change Percent | 0.9453924 |
| Fifty Two Week Range | 0.586 - 52.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,668,522,600,000 |
| Float Shares | 2,042,372 |
| Free Cashflow | -5,386,203 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04461 |
| Held Percent Institutions | 0.0044299997 |
| Implied Shares Outstanding | 2,394,806 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-11-15 |
| Language | en-US |
| Last Fiscal Year End | 1,761,868,800 |
| Last Split Date | 1,765,756,800 |
| Last Split Factor | 1:40 |
| Long Business Summary | Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; Polyrizon Ltd. to develop novel intranasal MEAI formulation; and NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. |
| Long Name | Clearmind Medicine Inc. |
| Market | us_market |
| Market Cap | 2,730,078 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_546305599 |
| Most Recent Quarter | 1,769,817,600 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -6,639,945 |
| Next Fiscal Year End | 1,793,404,800 |
| Non Diluted Market Cap | 2,730,078 |
| Open | 1.33 |
| Operating Cashflow | -5,554,012 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 973 536 1016 |
| Pre Market Change | -0.17469996 |
| Pre Market Change Percent | -15.324557 |
| Pre Market Price | 0.9653 |
| Pre Market Time | 1,776,770,555 |
| Prev Name | Cyntar Ventures Inc. |
| Previous Close | 0.7196 |
| Price Hint | 4 |
| Price To Book | 0.20753686 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.712 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.4204 |
| Regular Market Change Percent | 58.4213 |
| Regular Market Day High | 1.52 |
| Regular Market Day Low | 1.05 |
| Regular Market Day Range | 1.05 - 1.52 |
| Regular Market Open | 1.33 |
| Regular Market Previous Close | 0.7196 |
| Regular Market Price | 1.14 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 215,419,686 |
| Return On Assets | -0.55215 |
| Return On Equity | -1.19724 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,394,806 |
| Shares Percent Shares Out | 0.0197 |
| Shares Short | 47,081 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 103,059 |
| Short Name | Clearmind Medicine Inc. |
| Short Percent Of Float | 0.0197 |
| Short Ratio | 0.26 |
| Source Interval | 15 |
| State | BC |
| Symbol | CMND |
| Total Cash | 10,347,204 |
| Total Cash Per Share | 4.954 |
| Total Debt | 7,977 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -24.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.59516 |
| Two Hundred Day Average Change | -18.45516 |
| Two Hundred Day Average Change Percent | -0.9418224 |
| Type Disp | Equity |
| Volume | 215,419,686 |
| Website | https://www.clearmindmedicine.com |
| Zip | V6H 1A5 |